FOR IMMEDIATE RELEASE

TherapeuticsMD receives five new patent allowances, further strengthens IP assets

BOCA RATON, Fla., December 15, 2014 – TherapeuticsMD Inc. (NYSE MKT: TXMD), an innovative women’s healthcare company, today announced the U.S. Patent and Trademark Office (USPTO) has approved five new allowances for patents related to the company’s proprietary SYMBODA™ technology platform.

The new allowances are U.S. patent application Nos. 14/099,582; 14/099,598; 14/099,612 and 14/099,623, related to dosage formulations of the company’s combination bio-identical estradiol and progesterone hormone compositions. The USPTO also allowed U.S. patent application No. 14/099,562, directed to pharmaceutical compositions of the company’s combination bio-identical estradiol and progesterone hormone platform.

“These allowances continue our efforts to fortify our dynamic and growing intellectual property portfolio,” said TherapeuticsMD CEO Robert G. Finizio, “and they underscore the innovation of SYMBODA as a unique technology platform for the development of our investigational bio-identical hormone therapy products for women.”

About TherapeuticsMD
TherapeuticsMD Inc. is an innovative healthcare company focused on developing and commercializing products exclusively for women. With its patented SYMBODA™ technology platform, TherapeuticsMD is developing advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. The company’s clinical development pipeline includes two phase 3 products. The company also manufactures and distributes branded and generic prescription prenatal vitamins as well as over-the-counter vitamins and cosmetics under the vi taMedMD® and BocaGreenMD® brands. More information is available at the following websites: www.therapeuticsmd.com, www.vitamedmd.com, www.vitamedmdrx.com and www.bocagreenmd.com.

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD’s objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other
factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the company’s control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in the company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and include the following: the company’s ability to maintain or increase sales of its products; its ability to develop, protect and defend its intellectual property; its ability to develop and commercialize its hormone therapy drug candidates and obtain additional financing necessary therefor; the length, cost and uncertain results of its clinical trials; the potential of adverse side effects or other safety risks that could preclude the approval of the company’s hormone therapy drug candidates; its reliance on third parties to conduct its clinical trials, research and development and manufacturing; the availability of reimbursement from government authorities and health insurance companies for the company’s products; the impact of product liability lawsuits; and the influence of extensive and costly government regulation.

PDF copies of the company’s historical press releases and financial tables can be viewed and downloaded at our website: www.therapeuticsmd.com/pressreleases.aspx.

###

Contacts:

Dan Cartwright  
Chief Financial Officer  
561-961-1900  
Dan.Cartwright@TherapeuticsMD.com

Julia Amadio  
Chief Product Officer  
561-961-1900  
Julia.Amadio@TherapeuticsMD.com